Drug Trial Radar · NCT00671086
Efficacy of Ramelteon in Subjects With Chronic Insomnia
Last checked: Nov 20, 2026Latest source record: Feb 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,213
Actual
Start
Feb 2003
Primary completion
Sep 2004
Study completion Sep 2004
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- May 5, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the long-term safety of Ramelteon, once daily (QD), in subjects with chronic insomnia.
Conditions
- Sleep Initiation and Maintenance Disorders
Interventions
RamelteonDrug
Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.
RamelteonDrug
Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events.Time frame: Week 1, Months 1, 2, 3, 4, 6, 8, 10, and 12 or Final Visit.
- Change from Baseline in Vital Signs.Time frame: Week 1, Months 1, 2, 3, 4, 6, 8, 10, and 12 or Final Visit
- Change from Baseline in Hematology Laboratory Tests.Time frame: Week 1, Months 1, 2, 4, 6, 8, 10, and 12 or Final Visit.
- Change from Baseline in Chemistry Laboratory Tests.Time frame: Week 1, Months 1, 2, 4, 6, 8, 10, and 12 or Final Visit.
- Change from Baseline in Urinalysis Laboratory Tests.Time frame: Week 1, Months 1, 2, 4, 6, 8, 10, and 12 or Final Visit.
- Electrocardiograms.Time frame: Month 6 and 12 or Final Visit.
- Menstrual Diary Results.Time frame: Week 1, Months 1, 2, 4, 6, 8, 10, and 12 or Final Visit.
- Physical Examinations.Time frame: Months 2, 4, 8, 10, and 12 or Final Visit.
Locations
122 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Phoenix, Arizona
Site not named
Tempe, Arizona
Site not named
Hot Springs, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Burbank, California
Site not named
Cerritos, California
Site not named
Irvine, California
Site not named
La Jolla, California
Site not named
La Mesa, California
Site not named
Lafayette, California
Site not named
Murrieta, California
Site not named
Newport Beach, California
Site not named
Northridge, California
Site not named
Redlands, California
Site not named
Riverside, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Santa Monica, California
Site not named
Boulder, Colorado
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Site not named
Pueblo, Colorado
Site not named
Wheat Ridge, Colorado
Site not named
Wilmington, Delaware
Site not named
Brandon, Florida
Site not named
Clearwater, Florida
Site not named
DeLand, Florida
Site not named
Edgewater, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Largo, Florida
Site not named
Miami, Florida
Site not named
Naples, Florida
Site not named
New Smyrna Beach, Florida
Site not named
Ocala, Florida
Site not named
Safety Harbor, Florida
Site not named
St. Petersburg, Florida
Site not named
Stuart, Florida
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.